31 recruiting, 26 completed, 21 terminated, 20 active not recruiting. 81 Phase 1, 61 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Recurrent Acute Myeloid Leukemia: new trials by email Literature Review of Recurrent Acute Myeloid Leukemia trials Research Report on Recurrent Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-23 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Roswell Park Cancer Institute | 26 | 2026-02-02 | 2026-09-24 |
| Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia Anti-LILRA6 CAR-T cells - Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 48 | 2025-12-01 | 2025-12-04 |
| MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-10-24 | 2026-09-01 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-10-01 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-06-07 | 2025-05-25 | |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-10-16 |
| DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial Decoy-resistant interleukin-18, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Suspended | Fred Hutchinson Cancer Center | 40 | 2024-09-23 | 2026-08-10 |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Eltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy - Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 60 | 2024-08-14 | 2026-08-19 |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib - Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | Phase 1 | Recruiting | Uma Borate | 30 | 2024-02-20 | 2026-05-14 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 1 | 2023-08-14 | 2026-01-09 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 |
Showing 20 of 115. Sign in to see all of them.
Leukemia, Myeloid, Acute (115) · Myelodysplastic Syndromes (48) · Leukemia, Myelomonocytic, Chronic (24) · Leukemia, Biphenotypic, Acute (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Blast Crisis (9) · Myeloproliferative Disorders (9) · Myelodysplastic-Myeloproliferative Diseases (8) · Hematologic Neoplasms (7) · Hodgkin Disease (6) · Leukemia, Myeloid, Accelerated Phase (6) · Lymphoma, Non-Hodgkin (6) · Anemia, Refractory, with Excess of Blasts (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4)
Hematologic Diseases (115) · Hemic and Lymphatic Diseases (115) · Neoplasms (115) · Neoplasms by Histologic Type (115) · Leukemia (114) · Leukemia, Myeloid (114) · Bone Marrow Diseases (60) · Chronic Disease (33) · Disease Attributes (33) · Pathologic Processes (33) · Pathological Conditions, Signs and Symptoms (33) · Immune System Diseases (30) · Immunoproliferative Disorders (30) · Lymphatic Diseases (30) · Lymphoproliferative Disorders (29)
venetoclax (36) · Cytarabine (29) · Injections (26) · Specimen Handling (21) · Decitabine (20) · Azacitidine (19) · Biopsy (17) · fludarabine phosphate (16) · Cyclophosphamide (14) · fludarabine (12) · Whole-Body Irradiation (10) · Mycophenolic Acid (9) · decitabine and cedazuridine drug combination (9) · CPX-351 (8) · Filgrastim (8)
M.D. Anderson Cancer Center (49) · National Cancer Institute (NCI) (14) · City of Hope Medical Center (13) · Fred Hutchinson Cancer Center (10) · Children's Oncology Group (4) · OHSU Knight Cancer Institute (4) · Roswell Park Cancer Institute (3) · University of Washington (3) · Vanderbilt-Ingram Cancer Center (2) · Brian Jonas (1) · CicloMed LLC (1) · Jennifer Saultz (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · Racura Oncology Ltd (1)
United States (108) · Canada (2) · Australia (1) · China (1)
Courtney DiNardo, MD (5) · Tapan M Kadia (5) · Brian A Jonas (3) · Elizabeth Krakow (3) · Gautam Borthakur (3) · Musa Yilmaz (3) · Naval Daver (3) · Naval G Daver (3) · Nicholas Short (3) · Amanda Blackmon (2) · Courtney DiNardo (2) · Farhad Ravandi-Kashani (2) · Guido Marcucci (2) · Maria Luisa Sulis (2) · Mary-Elizabeth Percival (2)
PMID 40513054, PMID 27410923, PMID 29042364, PMID 29702001, PMID 30335787, PMID 31235963, PMID 32478814, PMID 32896301, PMID 33027528, PMID 33208914, PMID 33580980, PMID 33609248, PMID 33720354, PMID 33792630, PMID 34255353, PMID 34312462, PMID 34329576, PMID 34474640, PMID 34889407, PMID 34980577, PMID 35007144, PMID 35078972, PMID 35442137, PMID 36658425, PMID 36706355, PMID 36841758, PMID 37386016, PMID 37611156, PMID 38277619, PMID 38391202, PMID 38452788, PMID 38683966, PMID 39303729, PMID 39821392, PMID 39863139, PMID 40000842, PMID 40073835, PMID 40193193, PMID 40401707, PMID 40500616, PMID 40979071, PMID 41796974, PMID 42007254, PMID 42013378, PMID 42200455, PMID 42835577
P30CA033572 (12), P30CA016672 (6), P30CA015704 (5), UM1CA186709 (3), UM1CA186717 (3), UM1CA228823 (3), P01CA018029 (2), P01CA078902 (2), U10CA180886 (2), UM1CA186644 (2), UM1CA186691 (2), P01CA049639 (1), P30CA006516 (1), P30CA060553 (1), P30CA072720 (1)